{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T07:25:51Z","timestamp":1780385151975,"version":"3.54.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003827","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","award":["K21_137948"],"award-info":[{"award-number":["K21_137948"]}],"id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003827","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","award":["FK20_134253"],"award-info":[{"award-number":["FK20_134253"]}],"id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005909","name":"Ministry for Innovation and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005909","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003825","name":"Magyar Tudom\u00e1nyos Akad\u00e9mia","doi-asserted-by":"publisher","award":["\\u00DANKP-20-5-SE-22"],"award-info":[{"award-number":["\\u00DANKP-20-5-SE-22"]}],"id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003825","name":"Magyar Tudom\u00e1nyos Akad\u00e9mia","doi-asserted-by":"publisher","award":["\\u00DANKP-19-3-I-SE-52"],"award-info":[{"award-number":["\\u00DANKP-19-3-I-SE-52"]}],"id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003825","name":"Magyar Tudom\u00e1nyos Akad\u00e9mia","doi-asserted-by":"publisher","award":["BO\/00320\/18\/5"],"award-info":[{"award-number":["BO\/00320\/18\/5"]}],"id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005881","name":"Emberi Eroforr\u00e1sok Miniszt\u00e9riuma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005881","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002332","name":"Semmelweis Egyetem","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015498","name":"Innov\u00e1ci\u00f3s \u00e9s Technol\u00f3giai Miniszt\u00e9rium","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015498","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.pathol.2021.04.008","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T07:31:09Z","timestamp":1627457469000},"page":"95-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9127-5015","authenticated-orcid":false,"given":"Ambrus","family":"G\u00e1ng\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rich\u00e1rd","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eid","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8745-0757","authenticated-orcid":false,"given":"Judit","family":"Demeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Be\u00e1ta","family":"De\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00f3ra","family":"L\u00e9vai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5089-7659","authenticated-orcid":false,"given":"Lili","family":"Kotmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don\u00e1t","family":"Alp\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Matolcsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba","family":"B\u00f6d\u00f6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"M\u00e1trai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6210-8154","authenticated-orcid":false,"given":"Botond","family":"Tim\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2021.04.008_bib1","series-title":"World Health Organization Classification of Tumours of Hematopoietic and Lymphoid Tissues","first-page":"180","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma","author":"Campo","year":"2017"},{"key":"10.1016\/j.pathol.2021.04.008_bib2","first-page":"1146","article-title":"Richter's transformation in chronic lymphocytic leukemia","volume":"26","author":"Jain","year":"2012","journal-title":"Oncology"},{"key":"10.1016\/j.pathol.2021.04.008_bib3","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/PAS.0b013e31804bdaf8","article-title":"IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution","volume":"31","author":"Mao","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2021.04.008_bib4","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-08-3266","article-title":"Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2021.04.008_bib5","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2021.04.008_bib6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2141.2011.08907.x","article-title":"Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature","volume":"156","author":"Bockorny","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2021.04.008_bib7","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/cncr.22121","article-title":"Hodgkin transformation of chronic lymphocytic leukemia: the MD Anderson Cancer Center experience","volume":"107","author":"Tsimberidou","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2021.04.008_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.seminoncol.2016.02.012","article-title":"Richter syndrome: pathogenesis and management","volume":"43","author":"Rossi","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1016\/j.pathol.2021.04.008_bib9","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/sj.leu.2403249","article-title":"Relationship between the mutational status of VH genes and pathogenesis of diffuse large B-cell lymphoma in Richter's syndrome","volume":"18","author":"Tim\u00e1r","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2021.04.008_bib10","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1182\/blood-2018-01-791376","article-title":"Biology and treatment of Richter syndrome","volume":"131","author":"Rossi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2021.04.008_bib11","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","article-title":"Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax","volume":"129","author":"Anderson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2021.04.008_bib12","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/cncr.30596","article-title":"Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2021.04.008_bib13","doi-asserted-by":"crossref","first-page":"5646","DOI":"10.1182\/blood-2008-01-129726","article-title":"CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome?","volume":"111","author":"Aydin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2021.04.008_bib14","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11899-014-0223-4","article-title":"Risk factors for Richter syndrome in chronic lymphocytic leukemia","volume":"9","author":"Parikh","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.pathol.2021.04.008_bib15","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2141.2010.08482.x","article-title":"A\u00a0variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome","volume":"152","author":"Rasi","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2021.04.008_bib16","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2011-09-379966","article-title":"Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia","volume":"119","author":"Rossi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2021.04.008_bib17","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2012.09155.x","article-title":"Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"158","author":"Rossi","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2021.04.008_bib18","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/leu.2012.357","article-title":"NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome","volume":"27","author":"Villamor","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2021.04.008_bib19","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","article-title":"Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome","volume":"122","author":"Chigrinova","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2021.04.008_bib20","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1084\/jem.20131448","article-title":"Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome","volume":"210","author":"Fabbri","year":"2013","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.pathol.2021.04.008_bib21","first-page":"1405","article-title":"Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma","volume":"91","author":"Rossi","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2021.04.008_bib22","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/leu.2016.113","article-title":"Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL","volume":"30","author":"Maurer","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2021.04.008_bib23","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2013-11-516229","article-title":"How we treat Richter syndrome","volume":"123","author":"Parikh","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2021.04.008_bib24","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2008.07166.x","article-title":"Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome","volume":"142","author":"Rossi","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2021.04.008_bib25","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients","volume":"162","author":"Parikh","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2021.04.008_bib26","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2141.2007.06801.x","article-title":"Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia","volume":"139","author":"Maddocks-Christianson","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2021.04.008_bib27","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pathol.2021.04.008_bib28","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2017-12-820910","article-title":"Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study","volume":"131","author":"Ahn","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2021.04.008_bib29","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2021.04.008_bib30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2021.04.008_bib31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial","volume":"16","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2021.04.008_bib32","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2021.04.008_bib33","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2021.04.008_bib34","article-title":"Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: from patient material to sequence interpretation","volume":"141","author":"Agathangelidis","year":"2018","journal-title":"J\u00a0Vis Exp"},{"key":"10.1016\/j.pathol.2021.04.008_bib35","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/leu.2017.125","article-title":"Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations","volume":"31","author":"Rosenquist","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2021.04.008_bib36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/bjh.13562","article-title":"Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells","volume":"171","author":"Evans","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2021.04.008_bib37","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/bjh.14062","article-title":"Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors","volume":"177","author":"Chan","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2021.04.008_bib38","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.pathol.2021.04.008_bib39","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/PAS.0b013e31826cb1d1","article-title":"Plasmablastic transformation of low-grade B-cell lymphomas: report on 6 cases","volume":"37","author":"Martinez","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2021.04.008_bib40","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.humpath.2013.04.008","article-title":"Plasmablastic transformation of low-grade CD5+ B-cell lymphoproliferative disorder with MYC gene rearrangements","volume":"44","author":"Pan","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.pathol.2021.04.008_bib41","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000505683","article-title":"Chronic lymphocytic leukemia with divergent Richter's transformation into a clonally related classical Hodgkin's and plasmablastic lymphoma: a case report","volume":"13","author":"Gasljevic","year":"2020","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.pathol.2021.04.008_bib42","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1002\/eji.1830231210","article-title":"The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages","volume":"23","author":"de Weers","year":"1993","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.pathol.2021.04.008_bib43","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/ijc.32502","article-title":"Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib","volume":"146","author":"Gango","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pathol.2021.04.008_bib44","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/17474086.2018.1435268","article-title":"Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?","volume":"11","author":"Lampson","year":"2018","journal-title":"Exp Rev Hematol"},{"key":"10.1016\/j.pathol.2021.04.008_bib45","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/bloodadvances.2016003632","article-title":"Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL","volume":"1","author":"Kadri","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2021.04.008_bib46","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2021.04.008_bib47","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2021.04.008_bib48","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2021.04.008_bib49","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41467-018-03170-7","article-title":"Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia","volume":"9","author":"Herling","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.pathol.2021.04.008_bib50","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302521003731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302521003731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:42:04Z","timestamp":1777434124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302521003731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0031302521003731"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2021.04.008","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2021.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V. on behalf of Royal College of Pathologists of Australasia.","name":"copyright","label":"Copyright"}]}}